Targeting lymphangiogenesis after islet transplantation prolongs islet allograft survival

Transplantation

Volumn 92, Issue 1, 2011, Pages 25-30

  Yin, Na ^a,c   Zhang, Nan ^b   Xu, Jiangnan ^a   Shi, Qixin ^a   Ding, Yaozhong ^a   Bromberg, Jonathan S ^a,c  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b MARSHALL UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NONE   (United States)

Author keywords

Allograft; Islet; Lymphangiogenesis; Tolerance

Indexed keywords

CD3 ANTIGEN; FINGOLIMOD; GLUCOSE; INSULIN; MONOCLONAL ANTIBODY; STREPTOZOCIN; SUNITINIB; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 3; VASCULOTROPIN RECEPTOR 3 ANTIBODY;

ALLOIMMUNITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG TARGETING; ENDOTHELIUM CELL; GLUCOSE BLOOD LEVEL; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOHISTOCHEMISTRY; IMMUNOLOGICAL TOLERANCE; INHIBITION KINETICS; KIDNEY GRAFT REJECTION; LYMPH VESSEL; LYMPH VESSEL ENDOTHELIUM; LYMPHANGIOGENESIS; LYMPHATIC DRAINAGE; LYMPHOCYTE MIGRATION; LYMPHOCYTIC INFILTRATION; MALE; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREAS ISLET TRANSPLANTATION; PATIENT MONITORING; PRIORITY JOURNAL; RECEPTOR BLOCKING; STREPTOZOCIN DIABETES; T LYMPHOCYTE;

ANIMALS; ANTIBODIES, MONOCLONAL; DIABETES MELLITUS, EXPERIMENTAL; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOSUPPRESSIVE AGENTS; INDOLES; ISLETS OF LANGERHANS TRANSPLANTATION; LYMPHANGIOGENESIS; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PROPYLENE GLYCOLS; PYRROLES; SPHINGOSINE; T-LYMPHOCYTES; TRANSPLANTATION TOLERANCE; TRANSPLANTATION, HOMOLOGOUS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3;

EID: 79959657080     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31821d2661     Document Type: Article

References (37)

1. Sundar SS, Ganesan TS. Role of lymphangiogenesis in cancer. J Clin Oncol 2007; 25: 4298.
2. Alitalo K, Tammela T, Petrova TV. Lymphangiogenesis in development and human disease. Nature 2005; 438: 946.
3. Angeli V, Ginhoux F, Llodrà J, et al. B cell-driven lymphangiogenesis in inflamed lymph nodes enhances dendritic cell mobilization. Immunity 2006; 24: 203.
4. Angeli V, Randolph GJ. Inflammation, lymphatic function, and dendritic cell migration. Lymphat Res Biol 2006; 4: 217.
5. Liao S, Ruddle NH. Synchrony of high endothelial venules and lymphatic vessels revealed by immunization. J Immunol 2006; 177: 3369.
6. Chen L, Hamrah P, Cursiefen C, et al. Vascular endothelial growth factor receptor-3 mediates induction of corneal alloimmunity. Nat Med 2004; 10: 813.
7. El-Chemaly S, Levine SJ, Moss J. Lymphatics in lung disease. Ann N Y Acad Sci 2008; 1131: 195.
8. Oliver G, Alitalo K. The lymphatic vasculature: Recent progress and paradigms. Annu Rev Cell Dev Biol 2005; 21: 457.
9. Hamrah P, Chen L, Zhang Q, et al. Novel expression of vascular endothelial growth factor receptor (VEGFR)-3 and VEGF-C on corneal dendritic cells. Am J Pathol 2003; 163: 57.
10. Dietrich T, Bock F, Yuen D, et al. Cutting edge: Lymphatic vessels, not blood vessels, primarily mediate immune rejections after transplantation. J Immunol 2010; 184: 535.
11. Huggenberger R, Ullmann S, Proulx ST, et al. Stimulation of lymphangiogenesis via VEGFR-3 inhibits chronic skin inflammation. J Exp Med 2010; 207: 2255.
12. Källskog O, Kampf C, Andersson A, et al. Lymphatic vessels in pancreatic islets implanted under the renal capsule of rats. Am J Transplant 2006; 6: 680.
13. Tammela T, Alitalo K. Lymphangiogenesis: Molecular mechanisms and future promise. Cell 2010; 140: 460.
14. Pepper MS, Skobe M. Lymphatic endothelium: Morphological, molecular and functional properties. J Cell Biol 2003; 163: 209.
15. Karpanen T, Alitalo K. Molecular biology and pathology of lymphangiogenesis. Annu Rev Pathol 2008; 3: 367.
16. O'Farrell AM, Abrams TJ, Yuen HA, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003; 101: 3597.
17. Ledgerwood LG, Lal G, Zhang N, et al. The sphingosine 1-phosphate receptor 1 causes tissue retention by inhibiting the entry of peripheral tissue T lymphocytes into afferent lymphatics. Nat Immunol 2008; 9: 42.
18. Ebos JM, Lee CR, Christensen JG, et al. Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc Natl Acad Sci USA 2007; 104: 17069.
19. Tammela T, Zarkada G, Wallgard E, et al. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature 2008; 454: 656.
20. Guo R, Zhou Q, Proulx ST, et al. Inhibition of lymphangiogenesis and lymphatic drainage via vascular endothelial growth factor receptor 3 blockade increases the severity of inflammation in a mouse model of chronic inflammatory arthritis. Arthritis Rheum 2009; 60: 2666.
21. Baluk P, Tammela T, Ator E, et al. Pathogenesis of persistent lymphatic vessel hyperplasia in chronic airway inflammation. J Clin Invest 2005; 115: 247.
22. Brinkmann V, Davis MD, Heise CE, et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 2002; 277: 21453.
23. Henning G, Ohl L, Junt T, et al. CC chemokine receptor 7-dependent and -independent pathways for lymphocyte homing: Modulation by FTY720. J Exp Med 2001; 194: 1875.
24. Mandala S, Hajdu R, Bergstrom J, et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 2002; 296: 346.
25. Fu F, Hu S, Deleo J, et al. Long-term islet graft survival in streptozotocinand autoimmune-induced diabetes models by immunosuppressive and potential insulinotropic agent FTY720. Transplantation 2002; 73: 1425.
26. Matloubian M, Lo CG, Cinamon G, et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor. Nature 2004; 427: 355.
27. Pappu R, Schwab SR, Cornelissen I, et al. Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1- phosphate. Science 2007; 316: 295.
28. Pytowski B, Goldman J, Persaud K, et al. Complete and specific inhibition of adult lymphatic regeneration by a novel VEGFR-3 neutralizing antibody. J Natl Cancer Inst 2005; 97: 14.
29. Leclers D, Durand K, Cook-Moreau J, et al. VEGFR-3, VEGF-C and VEGF-D mRNA quantification by RT-PCR in different human cell types. Anticancer Res 2006; 26: 1885.
30. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003; 9: 327.
31. Faivre S, Demetri G, Sargent W, et al. Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 2007; 6: 734.
32. Hipp MM, Hilf N, Walter S, et al. Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. Blood 2008; 111: 5610.
33. Defuentes G, Bladé JS, Berets O. Tyrosine kinase inhibitors for chronic myelogenous leukemia. N Engl J Med 2007; 357: 1556.
34. George S. Sunitinib, a multitargeted tyrosine kinase inhibitor, in the management of gastrointestinal stromal tumor. Curr Oncol Rep 2007; 9: 323.
35. Grimaldi AM, Guida T, D'Attino R, et al. Sunitinib: Bridging present and future cancer treatment. Ann Oncol 2007; 18(suppl 6): vi31.
36. Jansson L, Carlsson PO. Graft vascular function after transplantation of pancreatic islets. Diabetologia 2002; 45: 749.
37. Zhang N, Richter A, Suriawinata J, et al. Elevated vascular endothelial growth factor production in islets improves islet graft vascularization. Diabetes 2004; 53: 963.